Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

  • Technology appraisal guidance
  • TA1160
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Notes

Topic selection